• SRX Global bought senior secured debt in CERo Therapeutics Holdings to provide additional capital for CERo’s clinical programs.
• CERo has treated six patients in its Phase 1 CERTAIN-T trial; the latest three-patient cohort showed no dose-limiting toxicities.
• The study opened its third cohort, screening patients for a planned 1 billion cells per patient dose, including MDS and myelofibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SRX Global Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310730PRIMZONEFULLFEED9818062) on August 31, 2026, and is solely responsible for the information contained therein.